Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.

More >>


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.

Past Events

Investor Contacts

Rick Wanstall

Chief Financial Officer and Treasurer

LifeSci Advisors, LLC.

Hans C. Vitzthum